- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05268172
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
January 30, 2024 updated by: Affiliated Hospital of Jiangnan University
Single-arm Open Multicenter Study of IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion Tumors
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Malignant pleural effusion is a common complication of malignant tumor, which usually indicates that the patient has reached the advanced stage, and about 30-40% of the patients are stubborn and refractory cases.
The lack of standard therapeutic drugs and protocols in clinical practice seriously affects the anti-tumor treatment effect, quality of life and survival time of patients, and the prognosis is poor.
IFN-γ can significantly induce the high expression of the costimulatory molecule ICAM-1 on tumor cells, thereby enhancing the killing of TUMOR cells by T cells.
Moreover, IFN-γ can enhance the activity of CAR T cells in the presence of PD-L1-PD-1 pathway, and significantly improve the therapeutic effect of T cells on solid tumors.
IFN-γ is an approved clinical treatment with known side effects and well-established symptomatic treatment.
Although CIK is not a clinically approved drug, it has been used on a large scale in China with good safety and has entered the medical insurance of some provinces and cities.
Tcm is an improved CIK cell and has good safety.
Many clinical studies have been carried out, and no serious toxic and side effects have been observed.
Study Type
Interventional
Enrollment (Estimated)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: liu quan, doctor
- Phone Number: 15995299079
- Email: Quanliu.lq@outlook.com
Study Contact Backup
- Name: jiang li qing, postgraduate
- Phone Number: 15261479578
- Email: jjiangliq@163.com
Study Locations
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214000
- Recruiting
- Affiliated Hospital Of Jiangnan University
-
Contact:
- 劝 刘
- Phone Number: 15995299079
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female patients: ≥18 years old;
- Gastric cancer, colon cancer, lung cancer, lymphoma and other tumors confirmed by histology or cytology. The guidelines recommend entry to clinical trials in accordance with the standard treatment progression recommended by each disease guideline;
- According to iRECIST criteria, the patient should have at least one target lesion with measurable diameter line (tumor lesion CT scan length ≥10 mm, lymph node lesion CT scan short diameter ≥15 mm, scan thickness ≥ 5 mm); Or an unevaluable lesion, including but not limited to pleural effusion, bone metastasis, etc;
- ECOG physical condition score: 0-3;
- Estimated survival ≥3 months;
- Good function of major organs, that is, relevant examination indexes within the first 14 days of randomization meet the following requirements:(1)Routine blood test: 1)Hemoglobin ≥ 90 g/L (no blood transfusion within 14 days); 2)Neutrophil count > 1.5×109/L; 3)Platelet count ≥ 90×109/L; (2)Biochemical examination: 1)Total bilirubin ≤ 1.5×ULN (upper limit of normal value); 2)Serum alanine aminotransferase (ALT) or AST ≤ 2.5×ULN; ALT or AST ≤ 5×ULN if liver metastasis was present; 3)Endogenous creatinine clearance ≥ 60 mL /min (Cockcroft-Gault formula); (3)Cardiac Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%;
- Signed informed consent;
- Good compliance, family members agreed to cooperate with survival follow-up.
Exclusion Criteria:
- Participated in clinical trials of other drugs within four weeks;
- Patients have a history of other tumors, except cervical carcinoma in situ, treated squamous cell carcinoma or bladder epithelial tumor (Ta and TIS), or other malignant tumors that have received radical treatment (at least 5 years prior to enrollment);
- Patients with cardiac clinical symptoms or diseases that are not well controlled, such as NYHA grade 2 or above heart failure, unstable angina pectoris, myocardial infarction within 1 year, and clinically significant ventricular or ventricular arrhythmias requiring treatment or intervention;
- For female subjects: surgically sterilized, postmenopausal, or have agreed to use a medically approved contraceptive during study treatment and for 6 months after the study treatment period; Serum or urine pregnancy tests must be negative during the 7 days prior to study enrollment and must be non-lactation. Male subjects: patients who are surgically sterilized or who have agreed to use a medically approved contraceptive during and for 6 months after the study treatment period;
- Patients with active tuberculosis, bacterial or fungal infection (grade ≥2 of NCI-CTC, 3rd edition); Have HIV infection, HBV infection, HCV infection;
- Those who have a history of psychotropic drug abuse and cannot get rid of it or have mental disorders;
- The subject has any active autoimmune disease or a history of autoimmune disease (e.g., but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis, hyperthyroidism, hypothyroidism); Subjects with vitiligo or asthma in complete remission during childhood without any intervention as adults could be included; Subjects with asthma requiring medical intervention with bronchodilators were excluded);
- According to the judgment of the researcher, there are serious concomitant diseases that endanger the patient's safety or affect the patient's ability to complete the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IFN- Y combined with T cells
First, IFN-γ was combined with CIK cells.
After three failed treatments, the CIK cells were replaced with T cells.
After three failed treatments, CART cells were finally replaced.
|
A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient.
CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: From the time of diagnosis of tumor to death from any cause,From initiation of study treatment until date of death from any cause, up to 100 months
|
The last follow-up time of the lost patient; Patients who were still alive at the end of the study were at the end of follow-up
|
From the time of diagnosis of tumor to death from any cause,From initiation of study treatment until date of death from any cause, up to 100 months
|
Progression-free survival
Time Frame: From time of treatment to time of disease progression or death from any cause as assessed by the investigator at each treatment period
|
From time of treatment to time of disease progression or death
|
From time of treatment to time of disease progression or death from any cause as assessed by the investigator at each treatment period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rate
Time Frame: The tumor shrinks or stabilizes for a certain period of time,Lasts at least 4 weeks
|
Proportion of patients who had a best response rating of complete response, partial response, or stable disease
|
The tumor shrinks or stabilizes for a certain period of time,Lasts at least 4 weeks
|
Objective response rate
Time Frame: 8 weeks
|
Total response and partial response ratio
|
8 weeks
|
Molecular markers for efficacy prediction
Time Frame: 8 weeks
|
Prediction effect
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: quan liu, doctor, Affiliated Hospital Of Jiangnan University
- Study Director: liu quan, doctor, Affiliated Hospital Of Jiangnan University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 20, 2022
Primary Completion (Estimated)
December 30, 2024
Study Completion (Estimated)
December 30, 2025
Study Registration Dates
First Submitted
December 6, 2021
First Submitted That Met QC Criteria
February 24, 2022
First Posted (Actual)
March 7, 2022
Study Record Updates
Last Update Posted (Actual)
January 31, 2024
Last Update Submitted That Met QC Criteria
January 30, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1362566548
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The associated efficacy is uncertain
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pleural Effusion, Malignant
-
Sheng HuWuhan Binhui Biotechnology Co., Ltd.RecruitingMalignant Pleural Effusion | Malignant Peritoneal EffusionChina
-
Huazhong University of Science and TechnologyUnknownMalignant Ascites | Malignant Pleural Effusion,China
-
Clover Biopharmaceuticals AUS Pty LtdCompletedMalignant Pleural EffusionsAustralia
-
Johns Hopkins UniversityEnrolling by invitationMalignant Pleural EffusionsUnited States
-
Singapore General HospitalCompletedMalignant Pleural EffusionsSingapore
-
Naestved HospitalTerminatedMalignant Pleural Effusion | Exudative Pleural EffusionDenmark
-
Wuhan YZY Biopharma Co., Ltd.Not yet recruitingA Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLCNSCLC Stage IV | Malignant Pleural EffusionsChina
-
M.D. Anderson Cancer CenterTerminatedAdvanced Cancers | Malignant Pleural EffusionsUnited States
-
Eastern Regional Medical CenterRecruitingLoculated or Non-draining Malignant Pleural EffusionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingPleural NeoplasmUnited States
Clinical Trials on IFN-γ and CIK cells, Tcm cells or CAR T cells
-
University Hospital, Basel, SwitzerlandRecruitingCytomegalovirus Infections | EBV | Adenovirus Infection | Cytokine Capture System | Allogenic DiseaseSwitzerland
-
Yae-Jean KimMiltenyi Biotec B.V. & Co. KGWithdrawnCytomegalovirus InfectionsKorea, Republic of
-
Minerva Biotechnologies CorporationCity of Hope Medical CenterRecruitingMetastatic Breast CancerUnited States
-
Fuda Cancer Hospital, GuangzhouJinan University GuangzhouCompleted
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
Wuhan Sian Medical Technology Co., LtdWuhan Union Hospital, China; Xiangyang Central Hospital; Jingzhou Central Hospital and other collaboratorsUnknownB Cell Lymphoma | Acute Lymphoblastic LeukemiaChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedLymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic LymphomaUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinRecruitingAcute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved RemissionUnited States
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingMultiple Myeloma | New Diagnosis TumorChina
-
Peking University People's HospitalNot yet recruitingT-cell Non-Hodgkin's Lymphoma